Literature DB >> 26862059

CD10-positive myoepithelial cells are usually prominent around in situ lobular neoplasia of the breast and much less prominent or absent in DCIS.

Sami Shousha1, Georgina Forbes1, Ilona Hopkins1, Josephine Anne Wright1.   

Abstract

AIMS: To study the relationship between the neoplastic cells of in situ lobular neoplasia (ILN) and ductal carcinoma in situ (DCIS) and the surrounding CD10-positive myoepithelial cells.
MATERIALS AND METHODS: Twenty consecutive cases of ILN and 51 of DCIS were stained for CD10 using the immunoperoxidase technique. The presence of CD10-positive cells was assessed semiquantitatively on a scale of 0-3 where 0 indicates their absence and 3 indicates the presence of multiple layers, which can be focal.
RESULTS: Ninety per cent of ILN cases scored 3, compared with none of DCIS (p=0.0001). There was a significant relationship between DCIS grade and CD10 score, with the mean scores being 1.43, 0.82 and 0.5 for low, intermediate and high grade, respectively. CD10-positive cells were always present around low-grade DCIS, but absent in 27% of high-grade cases. CD10-positive cells were more frequent in ER-positive than in ER-negative DCIS, and in HER2-negative than in HER2-positive cases, but the difference was not statistically significant.
CONCLUSIONS: There is a distinct relationship between the type and grade of in situ neoplasia of the breast and the surrounding CD10-positive myoepithelial cells, suggesting the presence of a 'cross talk' between the two elements. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

Entities:  

Keywords:  BREAST; BREAST PATHOLOGY; IMMUNOHISTOCHEMISTRY

Mesh:

Substances:

Year:  2016        PMID: 26862059     DOI: 10.1136/jclinpath-2015-203408

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  2 in total

1.  Perturbed myoepithelial cell differentiation in BRCA mutation carriers and in ductal carcinoma in situ.

Authors:  Lina Ding; Ying Su; Anne Fassl; Kunihiko Hinohara; Xintao Qiu; Nicholas W Harper; Sung Jin Huh; Noga Bloushtain-Qimron; Bojana Jovanović; Muhammad Ekram; Xiaoyuan Zi; William C Hines; Maša Alečković; Carlos Gil Del Alcazar; Ryan J Caulfield; Dennis M Bonal; Quang-De Nguyen; Vanessa F Merino; Sibgat Choudhury; Gabrielle Ethington; Laura Panos; Michael Grant; William Herlihy; Alfred Au; Gedge D Rosson; Pedram Argani; Andrea L Richardson; Deborah Dillon; D Craig Allred; Kirsten Babski; Elizabeth Min Hui Kim; Charles H McDonnell; Jon Wagner; Ron Rowberry; Kristie Bobolis; Celina G Kleer; E Shelley Hwang; Joanne L Blum; Simona Cristea; Piotr Sicinski; Rong Fan; Henry W Long; Saraswati Sukumar; So Yeon Park; Judy E Garber; Mina Bissell; Jun Yao; Kornelia Polyak
Journal:  Nat Commun       Date:  2019-09-13       Impact factor: 14.919

2.  Discriminating the earliest stages of mammary carcinoma using myoepithelial and proliferative markers.

Authors:  Hendrika M Duivenvoorden; Alex Spurling; Sandra A O'Toole; Belinda S Parker
Journal:  PLoS One       Date:  2018-07-25       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.